TGTX vs. DCPH, GERN, VERA, MRVI, ARVN, DYN, KROS, AMPH, RCKT, and NAMS
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Deciphera Pharmaceuticals (DCPH), Geron (GERN), Vera Therapeutics (VERA), Maravai LifeSciences (MRVI), Arvinas (ARVN), Dyne Therapeutics (DYN), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Rocket Pharmaceuticals (RCKT), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.
TG Therapeutics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.
In the previous week, Deciphera Pharmaceuticals had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 42 mentions for Deciphera Pharmaceuticals and 38 mentions for TG Therapeutics. Deciphera Pharmaceuticals' average media sentiment score of 0.26 beat TG Therapeutics' score of 0.19 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
TG Therapeutics has a net margin of 14.24% compared to Deciphera Pharmaceuticals' net margin of -119.33%. TG Therapeutics' return on equity of 33.79% beat Deciphera Pharmaceuticals' return on equity.
TG Therapeutics has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics presently has a consensus price target of $29.83, suggesting a potential upside of 84.27%. Deciphera Pharmaceuticals has a consensus price target of $24.17, suggesting a potential downside of 4.76%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe TG Therapeutics is more favorable than Deciphera Pharmaceuticals.
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. 9.2% of TG Therapeutics shares are owned by insiders. Comparatively, 4.4% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
TG Therapeutics received 331 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Summary
TG Therapeutics beats Deciphera Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
